{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T10:10:10Z","timestamp":1750414210217,"version":"3.41.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00393-017-0334-0","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T07:15:40Z","timestamp":1498720540000},"page":"495-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Psoriasisarthritis","Psoriatic arthritis"],"prefix":"10.1007","volume":"76","author":[{"given":"M.","family":"K\u00f6hm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,29]]},"reference":[{"issue":"5","key":"334_CR1","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1365-2133.2008.09023.x","volume":"160","author":"K Reich","year":"2009","unstructured":"Reich K, Kruger K, Mossner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a\u00a0prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160(5):1040\u20131047","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"334_CR2","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1136\/ard.2004.032318","volume":"64","author":"PS Helliwell","year":"2005","unstructured":"Helliwell PS, Taylor WJ (2005) Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 64(Suppl 2):ii3\u20138","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"334_CR3","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates LC, Helliwell PS (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 62(7):965\u2013969","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10012","key":"334_CR4","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O\u2019Dwyer JL et al (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a\u00a0UK multicentre, open-label, randomised controlled trial. Lancet 386(10012):2489\u20132498","journal-title":"Lancet"},{"key":"334_CR5","unstructured":"AWMF. AWMF Therapieleitlinie der Psoriasis vulgaris [Leitlinie]. 2011 cited 2011. Available from: AWMF.org."},{"issue":"3","key":"334_CR6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M et\u00a0al (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499\u2013510","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"334_CR7","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/bjd.14667","volume":"174","author":"LC Coates","year":"2016","unstructured":"Coates LC, Murphy R, Helliwell PS (2016) New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol 174(6):1174\u20131178","journal-title":"Br J Dermatol"},{"issue":"2","key":"334_CR8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00105-016-3925-9","volume":"68","author":"F Behrens","year":"2017","unstructured":"Behrens F, Thaci D, Wollenhaupt J, Kruger K (2017) Psoriatic arthritis : Overview of drug therapy options and administration characteristics. Hautarzt 68(2):153\u2013169","journal-title":"Hautarzt"},{"issue":"7","key":"334_CR9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/keq102","volume":"49","author":"L Eder","year":"2010","unstructured":"Eder L, Chandran V, Ueng J, Bhella S, Lee KA, Rahman P et al (2010) Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 49(7):1367\u20131373","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"334_CR10","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatol (Oxford) 51(8):1368\u20131377","journal-title":"Rheumatol (Oxford)"},{"issue":"4","key":"334_CR11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","volume":"71","author":"A Baranauskaite","year":"2012","unstructured":"Baranauskaite A, Raffayova H, Kungurov NV, Kubanova A, Venalis A, Helmle L et al (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71(4):541\u2013548","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"334_CR12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3899\/jrheum.141596","volume":"43","author":"F Behrens","year":"2016","unstructured":"Behrens F, Koehm M, Arndt U, Wittig BM, Greger G, Thaci D et\u00a0al (2016) Does concomitant Methotrexate with Adalimumab influence treatment outcomes in patients with Psoriatic arthritis? Data from a\u00a0large observational study. J\u00a0Rheumatol 43(3):632\u2013639","journal-title":"J Rheumatol"},{"issue":"1","key":"334_CR13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","volume":"73","author":"KM Fagerli","year":"2014","unstructured":"Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rodevand E et al (2014) The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 73(1):132\u2013137","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"334_CR14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/BOR.0b013e328344fddb","volume":"23","author":"F Behrens","year":"2011","unstructured":"Behrens F, Koehm M, Burkhardt H (2011) Update 2011: leflunomide in rheumatoid arthritis \u2013 strengths and weaknesses. Curr Opin Rheumatol 23(3):282\u2013287","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"334_CR15","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"JP Kaltwasser","year":"2004","unstructured":"Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a\u00a0multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50(6):1939\u20131950","journal-title":"Arthritis Rheum."},{"issue":"3","key":"334_CR16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000091251","volume":"212","author":"P Nash","year":"2006","unstructured":"Nash P, Thaci D, Behrens F, Falk F, Kaltwasser JP (2006) Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212(3):238\u2013249","journal-title":"Dermatology"},{"issue":"2","key":"334_CR17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2133.1999.02977.x","volume":"141","author":"VC Ho","year":"1999","unstructured":"Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, Leon-Dorantes G, Atakan N et al (1999) Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a\u00a01-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 141(2):283\u2013291","journal-title":"Br J Dermatol"},{"issue":"11","key":"334_CR18","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3899\/jrheum.140876","volume":"41","author":"ML Acosta Felquer","year":"2014","unstructured":"Acosta Felquer ML, Coates LC, Soriano ER, Ranza R, Espinoza LR, Helliwell PS et\u00a0al (2014) Drug therapies for peripheral joint disease in psoriatic arthritis: a\u00a0systematic review. J\u00a0Rheumatol 41(11):2277\u20132285","journal-title":"J Rheumatol"},{"issue":"12","key":"334_CR19","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","volume":"39","author":"DO Clegg","year":"1996","unstructured":"Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T et\u00a0al (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39(12):2013\u20132020","journal-title":"Arthritis Rheum."},{"issue":"9","key":"334_CR20","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","volume":"43","author":"M Cutolo","year":"2016","unstructured":"Cutolo M, Myerson GE, Fleischmann RM, Liote F, Diaz-Gonzalez F, Van den Bosch F et al (2016) A phase III, randomized, controlled trial of Apremilast in patients with Psoriatic arthritis: results of the PALACE 2 trial. J\u00a0Rheumatol 43(9):1724\u20131734","journal-title":"J Rheumatol"},{"issue":"10","key":"334_CR21","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72(10):1613\u20131620","journal-title":"Ann. Rheum. Dis."},{"key":"334_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15023","author":"J Zweegers","year":"2017","unstructured":"Zweegers J, Groenewoud JM, van den Reek JM, Otero ME, van de Kerkhof PC, Driessen RJ et al (2017) Comparison of the one and 5\u2011years effectiveness of adalimumab, etanercept and ustekinumab in psoriasis patients in daily clinical practice: results from the prospective BioCAPTURE registry. Br J Dermatol. doi: 10.1111\/bjd.15023","journal-title":"Br J Dermatol"},{"issue":"9625","key":"334_CR23","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y et al (2008) Efficacy and safety of ustekinumab, a\u00a0human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a\u00a0randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665\u20131674","journal-title":"Lancet"},{"issue":"9625","key":"334_CR24","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N et al (2008) Efficacy and safety of ustekinumab, a\u00a0human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a\u00a0randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675\u20131684","journal-title":"Lancet"},{"issue":"9894","key":"334_CR25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382(9894):780\u2013789","journal-title":"Lancet"},{"issue":"6","key":"334_CR26","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S et al (2014) Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6\u2011month and 1\u2011year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73(6):990\u2013999","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"334_CR27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D et al (2015) Secukinumab inhibition of Interleukin-17A in patients with Psoriatic arthritis. N Engl J Med 373(14):1329\u20131339","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"334_CR28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K et\u00a0al (2014) Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials. N Engl J Med 371(4):326\u2013338","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"334_CR29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","volume":"130","author":"JG Krueger","year":"2012","unstructured":"Krueger JG, Fretzin S, Suarez-Farinas M, Haslett PA, Phipps KM, Cameron GS et al (2012) IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J\u00a0Allergy Clin Immunol 130(1):145\u2013154","journal-title":"J Allergy Clin Immunol"},{"issue":"9993","key":"334_CR30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A et al (2015) Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 386(9993):541\u2013551","journal-title":"Lancet"},{"issue":"2","key":"334_CR31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","volume":"27","author":"PJ Mease","year":"2015","unstructured":"Mease PJ (2015) Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 27(2):127\u2013133","journal-title":"Curr Opin Rheumatol"},{"issue":"24","key":"334_CR32","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","volume":"370","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A et al (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N\u00a0Engl J Med 370(24):2295\u20132306","journal-title":"N Engl J Med"},{"issue":"6","key":"334_CR33","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jaad.2014.08.039","volume":"71","author":"K Papp","year":"2014","unstructured":"Papp K, Leonardi C, Menter A, Thompson EH, Milmont CE, Kricorian G et\u00a0al (2014) Safety and efficacy of brodalumab for psoriasis after 120\u00a0weeks of treatment. J\u00a0Am Acad Dermatol 71(6):1183\u20131190.e3","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"334_CR34","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jaad.2014.10.026","volume":"72","author":"K Papp","year":"2015","unstructured":"Papp K, Menter A, Strober B, Kricorian G, Thompson EH, Milmont CE et al (2015) Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol 72(3):436\u2013439.e1","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"334_CR35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.semarthrit.2015.10.001","volume":"45","author":"F Cantini","year":"2016","unstructured":"Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O, Favalli GE et al (2016) Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 45(5):519\u2013532","journal-title":"Semin. Arthritis Rheum."}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-017-0334-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0334-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0334-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T09:44:17Z","timestamp":1750412657000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-017-0334-0"}},"subtitle":["Aktuelle therapeutische Standards","Current therapeutic standards"],"short-title":[],"issued":{"date-parts":[[2017,6,29]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["334"],"URL":"https:\/\/doi.org\/10.1007\/s00393-017-0334-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2017,6,29]]}}}